Ratings by Leerink (Marc Goodman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | NervGen Pharma Corp | NGEN | New Coverage | Outperform (N/A) |
1.88 (1.67) |
-11.17% | Details | |
| 6/24/2026 | Rapport Therapeutics | RAPP | New Coverage | Outperform (N/A) |
38.88 (42.62) |
9.62% | Details | |
| 6/22/2026 | Definium Therapeutics Inc | DFTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2026 | Seaport Therapeutics | SPTX | New Coverage | Outperform (N/A) |
17.50 (20.85) |
19.14% | Details | |
| 4/15/2026 | Ovid Therapeutics Inc | OVID | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | AC Immune SA | ACIU | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2026 | Ovid Therapeutics Inc | OVID | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | Biohaven Pharma | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | SpyGlass Pharma | SGP | New Coverage | Outperform (N/A) |
26.73 (19.77) |
-26.04% | Details | |
| 3/2/2026 | Veradermics | MANE | New Coverage | Outperform (N/A) |
45.85 (111.32) |
142.79% | Details | |
| 1/23/2026 | Relmada Therapeutics Inc | RLMD | Upgrade | Outperform (Market Perform) |
3.96 (5.24) |
32.32% | Details | |
| 1/12/2026 | Neumora Therapeutics | NMRA | New Coverage | Outperform (N/A) |
2.33 (1.61) |
-30.9% | Details | |
| 12/31/2025 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2025 | Belite Bio, Inc, ADR | BLTE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2025 | MapLight Therapeutics | MPLT | New Coverage | Outperform (N/A) |
13.29 (37.87) |
184.95% | Details | |
| 11/17/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Outperform (N/A) |
1.31 (2.44) |
86.26% | Details | |
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2025 | Avadel Pharmaceuticals | AVDL | Downgrade | Market Perform (Outperform) |
18.53 (21.64) |
16.78% | Details | |
| 9/24/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2025 | Oculis Holding AG | OCS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2025 | Kalaris | KLRS | New Coverage | Outperform (N/A) |
4.79 (4.38) |
-8.56% | Details | |
| 3/25/2025 | Opthea Ltd. | OPT | Downgrade | Market Perform (Outperform) |
3.41 (3.41) |
0% | Details | |
| 12/30/2024 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2024 | Relmada Therapeutics Inc | RLMD | Downgrade | Market Perform (Outperform) |
2.77 (3.96) |
42.96% | Details | |
| 10/25/2024 | Alkermes | ALKS | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/18/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/14/2024 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
11.40 (29.05) |
154.82% | Details | |
| 10/14/2024 | MindMed | MNMD | New Coverage | Outperform (N/A) |
5.17 (15.02) |
190.52% | Details | |
| 10/7/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/5/2024 | Oculis Holding AG | OCS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2024 | LENZ Therapeutics Inc | LENZ | New Coverage | Outperform (N/A) |
21.89 (5.18) |
-76.34% | Details | |
| 3/11/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Market Perform (Outperform) |
3.36 (17.75) |
428.27% | Details | |
| 12/22/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Market Perform (Outperform) |
215.19 (329.83) |
53.27% | Details | |
| 10/6/2023 | Neurocrine Bio. | NBIX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2023 | Belite Bio, Inc, ADR | BLTE | New Coverage | Outperform (N/A) |
17.90 (150.08) |
738.44% | Details | |
| 7/24/2023 | Neurocrine Bio. | NBIX | Upgrade | Outperform (Market Perform) |
97.91 (170.88) |
74.53% | Details | |
| 6/12/2023 | Oculis Holding AG | OCS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2023 | Denali Therapeutics Inc. | DNLI | New Coverage | Outperform (N/A) |
31.47 (23.29) |
-25.99% | Details | |
| 1/24/2023 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Outperform (N/A) |
19.20 (15.44) |
-19.58% | Details | |
| 11/15/2022 | Satsuma Pharmaceuticals | STSA | Downgrade | Market Perform (Outperform) |
4.05 (1.10) |
-72.84% | Details | |
| 10/10/2022 | Satsuma Pharmaceuticals | STSA | Upgrade | Outperform (Market Perform) |
5.36 (1.10) |
-79.48% | Details | |
| 9/8/2022 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2022 | Eliem Therapeutics Inc. | ELYM | Maintain | Outperform (N/A) |
|
Details | ||
| 7/14/2022 | Karuna Therapeutics Inc. | KRTX | New Coverage | Outperform (N/A) |
128.87 (329.83) |
155.94% | Details | |
| 5/11/2022 | Biohaven Pharmaceutical Holding | BHVN | Downgrade | Market Perform (Outperform) |
83.14 (15.44) |
-81.43% | Details | |
| 4/26/2022 | Opthea Ltd. | OPT | New Coverage | Outperform (N/A) |
5.71 (3.41) |
-40.28% | Details | |
| 4/25/2022 | Eliem Therapeutics Inc. | ELYM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Gemini Therapeutics Inc. | GMTX | Downgrade | Market Perform (Outperform) |
1.40 (1.35) |
-3.57% | Details | |
| 11/23/2021 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/7/2021 | Eliem Therapeutics Inc. | ELYM | New Coverage | Outperform (N/A) |
27.56 (5.11) |
-81.46% | Details | |
| 7/28/2021 | Alkermes | ALKS | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/13/2021 | Graybug Vision | GRAY | Downgrade | Market Perform (Outperform) |
4.73 (5.50) |
16.28% | Details | |
| 3/12/2021 | Aldeyra Therapeutics | ALDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2021 | Graybug Vision | GRAY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/5/2020 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/2/2020 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/15/2020 | Marinus Pharmaceuticals | MRNS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2020 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/6/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2020 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2020 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/3/2020 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2020 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/6/2020 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2020 | Biogen | BIIB | New Coverage | Outperform (N/A) |
272.73 (205.99) |
-24.47% | Details | |
| 12/6/2019 | Sage Therapeutics | SAGE | Upgrade | Market Perform (Underperform) |
149.21 (8.68) |
-94.18% | Details | |
| 9/17/2019 | Alder Biopharm | ALDR | Downgrade | Market Perform (Outperform) |
10.06 (18.88) |
87.67% | Details | |
| 9/13/2019 | Acadia Pharmaceuticals | ACAD | Upgrade | Outperform (Market Perform) |
39.14 (25.60) |
-34.59% | Details | |
| 8/7/2019 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2019 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/18/2019 | Allergen | AGN | Downgrade | Market Perform (Outperform) |
164.26 (193.02) |
17.51% | Details | |
| 7/17/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2019 | Alder Biopharm | ALDR | New Coverage | Outperform (N/A) |
11.06 (10.06) |
-9.04% | Details | |
| 4/9/2019 | Zogenix, Inc. | ZGNX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/19/2019 | Vertex | VRTX | Downgrade | Market Perform (Outperform) |
188.09 (485.65) |
158.2% | Details | |
| 3/12/2019 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/7/2019 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2019 | AC Immune SA | ACIU | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2019 | Sage Therapeutics | SAGE | Maintain | Underperform (N/A) |
|
Details | ||
| 12/19/2018 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2018 | Zogenix, Inc. | ZGNX | New Coverage | Outperform (N/A) |
40.75 (26.68) |
-34.53% | Details | |
| 11/13/2018 | Adamas Pharmaceuticals | ADMS | New Coverage | Outperform (N/A) |
11.90 (8.22) |
-30.92% | Details | |
| 11/13/2018 | Allergen | AGN | New Coverage | Outperform (N/A) |
165.52 (164.26) |
-0.76% | Details | |
| 11/13/2018 | Vertex | VRTX | New Coverage | Outperform (N/A) |
180.55 (188.09) |
4.18% | Details | |
| 11/13/2018 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
356.66 (676.69) |
89.73% | Details | |
| 11/13/2018 | GW Pharma | GWPH | New Coverage | Outperform (N/A) |
137.87 (218.96) |
58.82% | Details | |
| 11/13/2018 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Outperform (N/A) |
38.92 (15.44) |
-60.33% | Details | |
| 11/13/2018 | Sage Therapeutics | SAGE | New Coverage | Underperform (N/A) |
130.94 (149.21) |
13.95% | Details | |
| 11/13/2018 | AC Immune SA | ACIU | New Coverage | Outperform (N/A) |
8.73 (2.20) |
-74.8% | Details | |
| 11/13/2018 | Neurocrine Bio. | NBIX | New Coverage | Market Perform (N/A) |
105.41 (170.88) |
62.11% | Details | |
| 11/13/2018 | Alkermes | ALKS | New Coverage | Market Perform (N/A) |
37.67 (52.72) |
39.95% | Details | |
| 11/13/2018 | Acadia Pharmaceuticals | ACAD | New Coverage | Market Perform (N/A) |
18.86 (39.14) |
107.53% | Details |
